Literature DB >> 19001322

Physicians' experiences with BRCA1/2 testing in community settings.

Nancy L Keating1, Kathryn A Stoeckert, Meredith M Regan, Lisa DiGianni, Judy E Garber.   

Abstract

PURPOSE: We surveyed a national sample of nonacademic physicians who ordered BRCA1/2 testing to understand their implementation of genetic testing and to assess recommendations for surveillance and cancer risk management of women with positive test results. PATIENTS AND METHODS: We surveyed physicians (N = 611 of 1,050; response rate, 58.2%) practicing in nonacademic settings who ordered BRCA1/2 testing during 2004 to 2005. We described physicians' experiences with testing and used multivariable regression models to identify factors associated with more complete counseling and with recommendations for cancer risk management for a BRCA1 mutation carrier.
RESULTS: Most physicians (68.2%) usually or always discussed six counseling items before testing. In adjusted analyses, physicians who were assisted by genetic counselors, nurse geneticists, or others (v counseling by themselves), those who spent more than 60 minutes in counseling, and medical oncologists (v surgeons or geneticists) were more likely to discuss all six items (all P < .05). A total of 61.4% of physicians would recommend bilateral prophylactic mastectomy to a 38-year-old BRCA1 mutation carrier who had completed childbearing. After adjustment, geneticists and gynecologists were less likely than medical oncologists and surgeons to recommend prophylactic mastectomy (P < .001), as were physicians in the Northeast versus those in other regions of the United States (P = .01).
CONCLUSION: Community-based physicians seem to be successfully incorporating BRCA1/2 testing into their practices. Physicians' recommendations for surveillance of mutation carriers are generally consistent with practice guidelines, yet recommendations for preference-based procedures such as prophylactic mastectomy vary by physician characteristics such as specialty and geographic region. The providers whom patients see for testing may contribute to variations in prophylactic treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001322      PMCID: PMC2645103          DOI: 10.1200/JCO.2008.17.8053

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  34 in total

1.  Physician use of genetic testing for cancer susceptibility: results of a national survey.

Authors:  Louise Wideroff; Andrew N Freedman; Lorayn Olson; Carrie N Klabunde; William Davis; Kadaba P Srinath; Robert T Croyle; Rachel Ballard-Barbash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-04       Impact factor: 4.254

2.  Prophylactic oophorectomy and hormone replacement therapy: protection at what price?

Authors:  Judy Ellen Garber; Anne-Renee Hartman
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

3.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

Authors:  Sunil R Lakhani; Marc J Van De Vijver; Jocelyne Jacquemier; Thomas J Anderson; Peter P Osin; Lesley McGuffog; Douglas F Easton
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

4.  BRCA1/2 genetic testing in the community setting.

Authors:  Wendy Y Chen; Judy E Garber; Suzanne Higham; Katherine A Schneider; Katie B Davis; Amie M Deffenbaugh; Thomas S Frank; Rebecca S Gelman; Frederick P Li
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

5.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

6.  Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination.

Authors:  Katrina Armstrong; Barbara Weber; Genevieve FitzGerald; John C Hershey; Mark V Pauly; Jean Lemaire; Krupa Subramanian; David A Asch
Journal:  Am J Med Genet A       Date:  2003-07-30       Impact factor: 2.802

7.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

8.  US physicians' attitudes toward genetic testing for cancer susceptibility.

Authors:  A N Freedman; L Wideroff; L Olson; W Davis; C Klabunde; K P Srinath; B B Reeve; R T Croyle; R Ballard-Barbash
Journal:  Am J Med Genet A       Date:  2003-07-01       Impact factor: 2.802

9.  Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.

Authors:  Beth N Peshkin; Claudine Isaacs; Clinton Finch; Sheryl Kent; Marc D Schwartz
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

View more
  23 in total

1.  Genetic counselor opinions of, and experiences with telephone communication of BRCA1/2 test results.

Authors:  A R Bradbury; L Patrick-Miller; D Fetzer; B Egleston; S A Cummings; A Forman; L Bealin; C Peterson; M Corbman; J O'Connell; M B Daly
Journal:  Clin Genet       Date:  2010-10-12       Impact factor: 4.438

2.  Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.

Authors:  T Pal; J-H Lee; A Besharat; Z Thompson; A N A Monteiro; C Phelan; J M Lancaster; K Metcalfe; T A Sellers; S Vadaparampil; S A Narod
Journal:  Clin Genet       Date:  2013-03-21       Impact factor: 4.438

3.  Physician Risk Assessment Knowledge Regarding BRCA Genetics Testing.

Authors:  Jason Cohn; William Blazey; David Tegay; Brian Harper; Sharon Koehler; Brookshield Laurent; Vivian Chan; Min-Kyung Jung; Bhuma Krishnamachari
Journal:  J Cancer Educ       Date:  2015-09       Impact factor: 2.037

4.  Physician interpretation of variants of uncertain significance.

Authors:  Sarah K Macklin; Jessica L Jackson; Paldeep S Atwal; Stephanie L Hines
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

Review 5.  Controversies in communication of genetic screening results for cancer: a report from the American Society of Preventive Oncology's Screening Special Interest Group (ASPO's 33rd Annual Meeting, March 8 to 10, 2009, Tampa, Florida).

Authors:  Linda Patrick-Miller; Angela R Bradbury; Mary Beth Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

6.  Educational needs and preferred methods of learning among Florida practitioners who order genetic testing for hereditary breast and ovarian cancer.

Authors:  Deborah Cragun; Andrea Doty Besharat; Courtney Lewis; Susan T Vadaparampil; Tuya Pal
Journal:  J Cancer Educ       Date:  2013-12       Impact factor: 2.037

7.  Evolution of Hereditary Breast Cancer Genetic Services: Are Changes Reflected in the Knowledge and Clinical Practices of Florida Providers?

Authors:  Deborah Cragun; Courtney Scherr; Lucia Camperlengo; Susan T Vadaparampil; Tuya Pal
Journal:  Genet Test Mol Biomarkers       Date:  2016-08-15

8.  A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer.

Authors:  Tuya Pal; Deborah Cragun; Courtney Lewis; Andrea Doty; Maria Rodriguez; Cristi Radford; Zachary Thompson; Jongphil Kim; Susan T Vadaparampil
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-28

9.  The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes.

Authors:  Nabil Amara; Jolyane Blouin-Bougie; Jalila Jbilou; Norrin Halilem; Jacques Simard; Réjean Landry
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

10.  Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida.

Authors:  S T Vadaparampil; C L Scherr; D Cragun; T L Malo; T Pal
Journal:  Clin Genet       Date:  2014-05-09       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.